Isis appoints new vice-president and chief medical officer
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals (US) has appointed Dr Martin Bedigian vice-president and chief medical officer, effective August 18th. In this position, Dr Bedigian will take the lead and be responsible for all medical aspects of Isis's clinical development programmes. He joins from Novartis Pharmaceuticals, where he was the global head of the cardiovascular assessment group.